Saturday , July 31 2021

Hepatitis C treatment may be shortened in 50 percent of patients, study findings



MAYWOOD, IL – Hepatitis C drugs treat more than 90 percent of patients, but may cost more than $ 50,000 per patient.

The findings of a new study can lead to significant cost savings. The preliminary data from the study conducted by Loyola University of Chicago Stritch School of Medicine and a theoretical modeling researcher from Loyola Medicine found that the standard 12-week treatment regimen in 50% of patients could be shortened to six weeks. without sacrificing activity.

The first author of the study, Loyola researcher Harel Dahari, who was the first author of Soroka University Medical Center's collaboration with Ohad Etzion, said, ad There is a potential to save up to 20 percent of the cost of hepatitis C drugs, Araştır he said. The senior author, Amir Shlomai, MD, PhD, from Beilinson Hospital in Israel.

The study was presented on November 12th during the annual meeting of the American Society for the Study of Liver Diseases in San Francisco.

Dahari is deputy director of Loyola Medical and Experimental and Theoretical Modeling Program (PETM) at the University of Loyola, Department of Hepatology, Chicago Stritch School of Medicine. The other two Loyola writers Susan Uprichard, PhD, Associate Director of PETM and Associate Professor of Microbiology and Immunology and Scott Cotler (MD), Professor of Medicine at Loyola University, and Professor of Medical Medicine at Loyola Medical School, Chicago Stritch School of Medicine.

Hepatitis C is an infection caused by a virus spreading through contaminated blood. Liver damage can lead to liver failure and liver cancer. An estimated 70 million people worldwide, including nearly three million in the United States, are chronically infected with hepatitis C.

A class of oral drugs called direct-acting anti-viral (DAA) changed the treatment of hepatitis C. In over 90 percent of patients, drugs eliminate the virus and treat the patient with minimal side effects. However, high cost limits constitute a significant financial burden on access to Medicare, Medicaid and private insurance companies.

”Treatment is now standardized so as to be given for a specific time period, usually 12 weeks, rather than for an individual patient,“ Cotler said.

In the new study, the researchers used a personalized medical technique called modeling-based response-guided therapy to reduce treatment times where possible. After patients were treated for several weeks, the researchers measured how much hepatitis C virus levels decreased. They used mathematical modeling to predict how long it would take to completely eliminate the virus.

To date, the study included 22 patients. Mathematical modeling predicted that in one patient (five percent of total patients), eight patients (36 percent) and two patients (nine percent) could be shortened to 10 weeks in six weeks. The other 11 patients (50%) had to be treated for 12 weeks.

Twenty-one patients remained virus-free. The only relapsed patient was the most difficult to treat hepatitis C virus known as genotype 3.

The concept proof pilot study showed that it was possible to use response-directed therapy to reduce treatment times. A large multi-center trial is under way in Israel to verify the results.

Moreover, he said, in addition to reducing costs, shorter treatment regimens would facilitate the treatment of hepatitis C patients, who are limited to the benefit of health insurance.

###

Prof. Dr. David Yardeni, MD, Anat Nevo-Shor, MD, Daniela Munteanu, MD and Naro Abufreha, MD, Soroka University Medical Center, Beesheba, Israel Department of Gastroenterology and Liver Diseases; Assaf Issachar, MD, Michal Cohen-Naftaly, MD, Orly Sneh Arbib, MD and Marius Braun, MD, Liver Institute, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel; and Ministry of Health, Sheba Medical Center, Israel Orna Mor, PhD.

Eler Response Guided Therapy with DAA A Shortens the Duration of Treatment in 50 Percent of Patients Treated with HCV. Çalış

The study was supported in part by a national health service organization in Israel, Clalit and the US National Institutes of Health.

Legal warning: AAAS and EurekAlert! Not responsible for the accuracy of newsletters sent to EurekAlert! To contribute to the use of institutions or any information through the EurekAlert system.


Source link